I am not an expert on biotech valuations, but in c

I am not an expert on biotech valuations, but in comparison to some other biotechs and pps we can maybe get an idea. First I was comparing CYDY to GERN to get an idea how undervalued it is. GERN just completed phase 2, has maybe 2 indications of blood type cancer, is a bit toxic and actually just got dropped by Janson (a subsidiary of johnson and johnson). CYDY has completed phase 3, is looking for approval and CYDY's market cap is about half of what GERN's is. Granted GERN is not on the OTC, probably helps. For a company already doing well. I see INCY (Incyte) just had a GvHD drug approved. Has about 460million in revenue per qtr the last 2 qtr's. Thats about what NP expects the first year. INCY's market cap is 17 billion. So if CYDY's annual revenue is the same as INCY's single quarter, can we take .25*17billion to get ~4billion market cap all things equal? Thats just with combo. Many times the market (in tech anyway) values on future earnings so we have to let mr. market decide how optimistic and excited they are of CYDY's potential in all their indications. So take what you will from that. Those pharma's may not be apple to apple comparisons, but I think it can help with ballpark estimations.